Open a clinical trial in anemic patients with chronic kidney disease
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Aug 2022
- Due
- 31 Dec 2022
- Delivered
- February 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“later this year we expect to be opening a trial in anemic patients with chronic kidney disease.”
What we found
Evidence strength A What the grades mean
The company announced in August 2022 that it expected to open a clinical trial for anemic patients with chronic kidney disease by year-end, but the trial was initiated in February 2023.
-
A Disc Medicine, Inc. 10-K filed 2023-03-31
“In February 2023, we initiated a Phase 1b/2 clinical trial to evaluate the safety, tolerability and efficacy of DISC-0974 in patients with CKD who are not receiving dialysis and are anemic.” ✓ confirmed on the page
Market reaction: the shares moved -5.2% against the S&P 500 over the three sessions around the disclosure (30 Mar 2023 to 4 Apr 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Open
- Deliverable
- Clinical trial for chronic kidney disease
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-IRON-002115 · Corrections policy